Latest news
2023-05 – Serodus ASA – Notice of General Meeting 2023
Norwegian VPS registred shareholders: VPS General Meeting
2023-05 – 2022 Annual Report
Serodus ASA – Publishes 2022 Annual Report
2023-04 – Q1 2023 Reporting
- Serodus has visited all clinical centers in Australia and New Zealand
- SER150/placebo dosing period has been prolonged from 3 to 6 months.
2023-02 – Q4 2022 Reporting
- New Zealand authorities approved the protocol with dosing of SER150 or placebo for six months.
- All clinical centers in Australia and New Zealand ready to initiate screening of patients in January for participation in study SER150 CL-009
2023-01 – New CEO in Serodus ASA
Serodus ASA’s Board of Directors has in agreement with our CEO Eva Steiness decided to relieve her for the administrative burden to manage Serodus ASA from her permanent address in Denmark.
Serodus Board has appointed Mr. Arnstein Endresen, previous member of the Board of Directors and decided to place/outsource all SER150 management to the 100% Serodus ASA owned Danish subsidiary, Serodus ApS.
Eva Steiness is the CEO in Serodus ApS and will in this capacity continue to manage SER150 development for the treatment of patients with Diabetic Kidney Disease.
2022-10 – Q3 2022 Reporting
- Transition to the new Australian based CRO was finalized during Q3.
- Australian ethical committee has approved increasing dosing period from 3 to 6 months.
- Reactivation of Australian centers by the new CRO.
- Centers in New Zealand are being added to the Australian centers.
2022-08 – Q2 2022 Reporting
- Still low number of patients entered the study in Q2-2022.
- A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.
- Complete transfer expected to be finalized mid Q3-2022.
- Australian ethical committee has approved increasing dosing period from 3 to 6 months.